Corbevax may be considered for a third/precaution dose six months after completion of primary series of Covaxin or Covishield vaccines for population above 18 years wherever indicated," the panel recommended.
The Covid working committee, in its July 20 meeting, reviewed data of the double-blind randomized phase-3 clinical study which evaluated the immunogenicity and safety of a booster dose of Corbevax vaccine when administered to Covid-19-negative adult volunteers of age 18-80 years previously vaccinated with two doses of either Covishield or Covaxin.
The Covid-19 working group observed that the Corbevax vaccine can induce a significant increase in antibody titers when given to those who have received either Covaxin or Covishield.
The Drugs Controller General of India (DCGI) on June 4 approved Corbevax as a precaution dose for those aged 18 and above. The Biological E's Covid-19 vaccine has also received approval from NTAGI for use among children aged between 5-12 years.